Suggestions
Lev Osherovich
Scientist, Company Builder, Investor
Lev Osherovich is a multifaceted professional with a diverse background spanning science, journalism, and venture capitalism. He is currently the Founding Director at StealthCo, a company based in Basel, Switzerland.1
Professional Background
Osherovich's career is characterized by his ability to bridge academic and industry knowledge to uncover unexpected therapeutic opportunities.1 His expertise lies in several key areas:
Scientific Research:: Osherovich has a strong foundation in biology, having been associated with the University of California, San Francisco.1
Journalism:: He has experience as a biotech journalist, which has likely contributed to his ability to communicate complex scientific concepts.
Venture Capitalism:: Osherovich has transitioned into the world of venture capital, bringing his scientific expertise to investment decisions in the biotech sector.
Current Role
As the Founding Director at StealthCo, Osherovich is involved in:
- Building companies
- Investing in promising biotech ventures
- Applying his scientific knowledge to identify therapeutic opportunities
Interests and Activities
Osherovich maintains an active presence on professional networks, often sharing insights on:
- RNA discoveries and their therapeutic applications, such as treatments for spinal muscular atrophy3
- Developments in cell therapy and contract development and manufacturing organizations (CDMOs)4
- Simulations for experiments in the pharmaceutical industry2
Lev Osherovich's unique combination of scientific expertise, journalistic experience, and venture capital acumen positions him as a valuable contributor to the biotech and pharmaceutical industries, particularly in identifying and developing novel therapeutic approaches.
Highlights
https://lnkd.in/dKKQbAN8
Unlike DNA, RNA plays numerous active roles in living cells. It acts as an enzyme, splicing and dicing other RNA molecules or assembling proteins — the stuff of which all life is built — from amino acid building blocks. It keeps stem cells active and forestalls aging by building out the DNA at the ends of our chromosomes.
RNA discoveries have led to new therapies, such as the use of antisense RNA to help treat children afflicted with the devastating disease spinal muscular atrophy. The mRNA vaccines, which saved millions of lives during the Covid pandemic, are being reformulated to attack other diseases, including some cancers. RNA research may also be helping us rewrite the future; the genetic scissors that give CRISPR its breathtaking power to edit genes are guided to their sites of action by RNAs.
Although most scientists now agree on RNA's bright promise, we are still only beginning to unlock its potential. Consider, for instance, that some 75 percent of the human genome consists of dark matter that is copied into RNAs of unknown function. While some researchers have dismissed this dark matter as junk or noise, I expect it will be the source of even more exciting breakthroughs.
We don’t know yet how many of these possibilities will prove true. But if the past 40 years of research have taught me anything, it is never to underestimate this little molecule.
Congratulations to Szabolcs Nagy, Daniel Veres MD PhD and the Turbine team on getting to the next level with this series A financing. Special thanks to Delin Ventures BoD member Natalia Novac for doing the hard work to make this dream a reality.
